Lawrence F Eichenfield

36PUBLICATIONS
119CO-AUTHORS
Gene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Infant and child healthTraditional Chinese medicine and treatmentsAdolescent health
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (36)

|Sep 04, 2026
Update on Approved Therapies for Dystrophic and Junctional Epidermolysis Bullosa.

|Aug 28, 2026
Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials.

|Aug 18, 2026
Growth Assessment in Children Under 12 Years With Moderate-to-Severe Atopic Dermatitis Included in the PEDISTAD Observational Registry.

|Mar 08, 2026
Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE).

Lawrence F Eichenfield, Mercedes E Gonzalez, Mark Boguniewicz

|Feb 08, 2026
Expert Recommendations for the Diagnosis and Management of Chronic Hand Eczema in the United States.

Jonathan I Silverberg, David Cohen, Emma Guttman-Yassky

|Apr 20, 2025
Patient-Reported Impact of Atopic Dermatitis on Pediatric and Adolescent Patients With Moderate-To-Severe Disease: Results of a Real-World, Cross-Sectional Survey.

Lawrence F Eichenfield, Vivian Y Shi, JiaDe Yu

Pageof 6

Frequent Collaborators

5 joint publications

Erin Almaraz

4 joint publications

Adelaide A Hebert

4 joint publications

Emma Guttman-Yassky

4 joint publications

Jonathan I Silverberg